Curiox Biosystems FY 2025 Annual Report
Beta

Filed: March 23, 2026· period ending December 31, 2025DART

Curiox Biosystems annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 23, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

Curiox Biosystems FY 2025 Annual Report Analysis

Business Overview

• Cell and gene therapy (CGT) focus in single-cell transcriptome and epitope indexing via CITE-Seq technology
• DropArray™ platform utilizing laminar flow wash (Laminar Wash™) introduced for non-disruptive cell cleaning

Management Discussion & Analysis

• Revenue KRW 5,152M in 2025, up 12.29% YoY; operating loss KRW 12,314M, reduced by 7.95% from prior year; net loss KRW 27,178M, wider by KRW 19,089M
• Pluto Wash new product portfolio drove revenue increase with KRW 313M product sales growth and KRW 251M from new installations

Risk Factors

• Put option on KRW 20B convertible bonds exercisable quarterly from July 26, 2026, at 100% principal amount
• Call option on up to 20% of bonds at principal + 1% annual compounded interest, exercisable daily from July 26, 2025 to July 26, 2026

Curiox Biosystems FY 2025 Key Financial Metrics
DART

Total Assets

KRW 78.0B

▲ +10.6% YoY

Operating Cash Flow

-KRW 11.1B

▼ -14.5% YoY

CapEx

KRW 136.1M

▼ -47.2% YoY

Source: KIFRS consolidated financial data from Curiox Biosystems annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding